{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-264714","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.418619+00:00","generated_at":"2026-05-29T19:01:54.846707+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IN8bio Phase 1 INB-200 data: 50% of multi-dose patients alive beyond expected median OS","bullets":["50% of multi-dose patients (n=10) alive beyond expected median OS from Stupp regimen; none in single-dose group (n=3).","Biopsy confirmed gamma-delta T cell persistence in brain tumor microenvironment in two patients post-treatment.","Median PFS in repeat-dose patients increased 79% vs. 6.9 months for Stupp regimen.","No treatment-related serious adverse events, cytokine release syndrome, or neurotoxicity reported.","One IDH-mutant glioma patient remains alive and progression-free at 40.5 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-264714","json":"https://secwatch.observer/filing/0001193125-24-264714.json","markdown":"https://secwatch.observer/filing/0001193125-24-264714.md","text":"https://secwatch.observer/filing/0001193125-24-264714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524264714/0001193125-24-264714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524264714/d844601d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:01:54.846707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}